Abstract
The process of tumor metastasis has been and remains perhaps the most difficult aspect of clinical oncology to diagnose, the study of which has received great attention in recent years. According to various authors, the frequency of metastasis in malignant neoplasms varies from 19-34% [1,2,5]. At the same time, it should be noted that some researchers highlight geographical features of the frequency of metastasis of individual tumors. Thus, in the countries of South America, the frequency of metastasis of lung cancer to parenchymal organs is recorded 2 times more often than in the countries of Southeast Asia, but this question remains rather rhetorical and highly debatable according to a number of scientists [5]. In recent years, approaches to the treatment of metastatic lesions have been modernized and improved. One way or another, surgical methods of exposure - metastasectomy, radiation therapy, drug therapy, including modern immuno and targeted agents - are widespread and applicable. [3,4]. At the same time, minimally invasive, highly effective treatment methods, radiofrequency ablation, are widely used in clinical practice. Radiofrequency ablation of primary and metastatic solid lesions is a method of exposure to radiofrequency ultrashort wave heating of tumor tissue with immediate cooling, a pronounced zone of demarcation and necrobiosis. According to the observations of Japanese colleagues, the median 5-year survival rate of metastatic colorectal cancer using radiofrequency ablation is 56%, while the same predictor reached 53% with metastasectomy, however, taking into account the length of hospitalization, the volume of intervention and the frequency of postoperative complications, the observations of Japanese colleagues are really impressive.Considering the clinical variability of metastatic lesions of parenchymal organs and their frequency of occurrence, the question of a minimally invasive, highly effective, clinically and economically justified method of treatment is acutely increasing